Company intelligence / Profile preview
Axcentua Pharmaceuticals AB
Stockholm, Stockholm, Swedenaxcentua.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
The lead asset AXP107‑11 has undergone Phase Ib/IIa studies to assess safety and efficacy in combination with gemcitabine for advanced pancreatic cancer. No published results are available as of the latest update. The company also explores rare disease applications and holds IP on its crystalline forms.
- Therapeutic areas
- OncologyRare DiseasesCardiovascular
- Modalities
- Small molecules (notably crystal re-engineered forms of natural compounds)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Axcentua Pharmaceuticals AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Axcentua Pharmaceuticals AB.